| pubmed-article:8166218 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8166218 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8166218 | lifeskim:mentions | umls-concept:C0543467 | lld:lifeskim |
| pubmed-article:8166218 | lifeskim:mentions | umls-concept:C0677886 | lld:lifeskim |
| pubmed-article:8166218 | lifeskim:mentions | umls-concept:C1301886 | lld:lifeskim |
| pubmed-article:8166218 | lifeskim:mentions | umls-concept:C0038952 | lld:lifeskim |
| pubmed-article:8166218 | lifeskim:mentions | umls-concept:C1609982 | lld:lifeskim |
| pubmed-article:8166218 | lifeskim:mentions | umls-concept:C0543478 | lld:lifeskim |
| pubmed-article:8166218 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:8166218 | lifeskim:mentions | umls-concept:C0443228 | lld:lifeskim |
| pubmed-article:8166218 | lifeskim:mentions | umls-concept:C0205225 | lld:lifeskim |
| pubmed-article:8166218 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:8166218 | pubmed:dateCreated | 1994-5-26 | lld:pubmed |
| pubmed-article:8166218 | pubmed:abstractText | The Gynecologic Oncology Group has divided patients with advanced epithelial ovarian cancer into those with optimal residual cancer, in which the maximum diameter of residual is < or = 1 cm, and suboptimal residual cancer, in which the residual disease is > 1 cm. Within the optimal group of patients there is a survival difference between patients with microscopic residual disease and those with any macroscopic disease < or = 1 cm. No analysis of the effect of various residual disease diameters in patients with residual disease > or = 1 cm has been performed. This study evaluates the effect of residual disease diameter in patients with suboptimal disease entered on a randomized trial of intense versus standard chemotherapy. | lld:pubmed |
| pubmed-article:8166218 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8166218 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8166218 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:8166218 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8166218 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:8166218 | pubmed:issn | 0002-9378 | lld:pubmed |
| pubmed-article:8166218 | pubmed:author | pubmed-author:BermanMM | lld:pubmed |
| pubmed-article:8166218 | pubmed:author | pubmed-author:CreasmanW TWT | lld:pubmed |
| pubmed-article:8166218 | pubmed:author | pubmed-author:BerekJ SJS | lld:pubmed |
| pubmed-article:8166218 | pubmed:author | pubmed-author:HoskinsW JWJ | lld:pubmed |
| pubmed-article:8166218 | pubmed:author | pubmed-author:McGuireW PWP | lld:pubmed |
| pubmed-article:8166218 | pubmed:author | pubmed-author:HomesleyH DHD | lld:pubmed |
| pubmed-article:8166218 | pubmed:author | pubmed-author:BradyM FMF | lld:pubmed |
| pubmed-article:8166218 | pubmed:author | pubmed-author:BallHH | lld:pubmed |
| pubmed-article:8166218 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8166218 | pubmed:volume | 170 | lld:pubmed |
| pubmed-article:8166218 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8166218 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8166218 | pubmed:pagination | 974-9; discussion 979-80 | lld:pubmed |
| pubmed-article:8166218 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:8166218 | pubmed:meshHeading | pubmed-meshheading:8166218-... | lld:pubmed |
| pubmed-article:8166218 | pubmed:meshHeading | pubmed-meshheading:8166218-... | lld:pubmed |
| pubmed-article:8166218 | pubmed:meshHeading | pubmed-meshheading:8166218-... | lld:pubmed |
| pubmed-article:8166218 | pubmed:meshHeading | pubmed-meshheading:8166218-... | lld:pubmed |
| pubmed-article:8166218 | pubmed:meshHeading | pubmed-meshheading:8166218-... | lld:pubmed |
| pubmed-article:8166218 | pubmed:meshHeading | pubmed-meshheading:8166218-... | lld:pubmed |
| pubmed-article:8166218 | pubmed:meshHeading | pubmed-meshheading:8166218-... | lld:pubmed |
| pubmed-article:8166218 | pubmed:meshHeading | pubmed-meshheading:8166218-... | lld:pubmed |
| pubmed-article:8166218 | pubmed:meshHeading | pubmed-meshheading:8166218-... | lld:pubmed |
| pubmed-article:8166218 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:8166218 | pubmed:articleTitle | The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. | lld:pubmed |
| pubmed-article:8166218 | pubmed:affiliation | Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York. | lld:pubmed |
| pubmed-article:8166218 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8166218 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8166218 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8166218 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8166218 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8166218 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8166218 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8166218 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8166218 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8166218 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8166218 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8166218 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8166218 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8166218 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8166218 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8166218 | lld:pubmed |
